GHO Capital backs biotech RoslinCT

The company serves blue-chip pharma and biotech companies, partnering from the development phase through to late-stage clinical manufacturing.

GHO says RoslinCT will now increase its development and manufacturing capacity, expand customer acquisition and further develop its product.

The GP has raised three funds to date, with the latest closing in May 2021 at more than EUR 2bn. 

Its predecessor, GHO Capital II, invested tickets of EUR 75m-100m. GHO Capital III invest in companies with enterprise values of EUR 100m-400m, and expects to make 10-14 platform investments.

GHO has not yet responded to Unquote's question on whether the stake is majority or minority, but a filing on Companies House shows that a company connected to GHO holds 75% or more of the share capital. 

The GP says that the advanced therapy market is forecast to grow at up to 50% annually.

Company
RoslinCT was established in 2006 as a spin-out from the Roslin Institute at the University of Edinburgh. Since 2014, it has had a manufacturing base in the university's Centre for Regenerative Medicine. It works in high-quality cell therapy development and manufacturing.

People
GHO Capital – Charles Cox (managing director, head of investor relations); Alan MacKay, Mike Mortimer, Andrea Ponti (managing partners, founders); Edward de Nor, Mike Turner, Ken Eichmann (partners); David Miller, Geoffrey Hamilton-Fairley (operating partners).
RoslinCT – Janet Downie (CEO)

Advisers
Equity – Slaughter & May (legal); Alvarez & Marsal (financial due diligence, tax); Deloitte (structuring), ClearView Healthcare Partners (commercial due diligence); Dark Horse Consulting (technical due diligence); ERM (ESG due diligence).
Vendor – Torreya Partners (financial due diligence); Dentons (legal). 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• Healthcare
• UK / Ireland
• Small-cap buyout